Placebo-controlled, parallel-group, multi-center trial will enroll around 400 patients to assess effects of AC-1204 on cognition, pharmacokinetic measures, daily living activities, resource utilization and quality of life among subjects.
Accera president and CEO Holger Kunze said, "With the recent investment we received from Nestlé Health Science, we’re eager to generate additional clinical data illustrating the effectiveness of our product in patients with mild-to-moderate Alzheimer’s disease."
Primary endpoint of the study is to find the AC-1204 effect on memory and cognition after 26 weeks as calculated by Alzheimer’s Disease Assessment Scale-cognitive subscale.
Endpoint is measured among both epsilon 4 variant carriers and non carriers of the gene apolipoprotein E (APOE4).